The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has affected lives of billions of individuals, globally. We also discuss the current progress in the development of adjuvanted vaccines against the disease. This review paper will discuss the experimental results of the adjuvanted vaccine studies with similar coronaviruses (CoVs) which might be useful to select an appropriate adjuvant for a vaccine against rapidly emerging SARS-CoV-2. Incorporating a suitable adjuvant in a SARS-CoV-2 vaccine may address these requirements. As the pandemic has hit most countries across the globe, there will be an overwhelming demand for the vaccine in a quick time. This decreases the cost of a vaccine and makes it affordable. Further, the vaccine should be able to induce protective levels of antibodies rapidly with the least amount of antigen used. However, to elicit the protective levels of antibodies, a vaccine may require multiple doses or assistance from other immunostimulatory molecules. An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors. The extensive efforts around the globe are being made to develop a suitable vaccine against COVID-19 (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). Stable CHO cell line expressing 50 mg/L of S1-Fc and a 3,000 L Bioreactor can produce 3 million doses of human COVID-19 vaccine every 10 days, making it an accessible and affordable option for worldwide vaccination S1-Fc protein solicits strong neutralizing activities against live virus Our data strongly suggests that the CHO-expressed SARS-CoV-2 S1-Fc recombinant protein could be a strong candidate for vaccine development against COVID-19.ĬHO-expressed S1-Fc protein is very immunogenic in various animals and can rapidly induce strong antibody production Most importantly, in less than 20 days and three injections of the S1-Fc fusion protein, two monkeys developed higher virus neutralizing titers than a recovered COVID-19 patient in a live SARS-CoV-2 infection assay. Strong virus neutralizing activity was observed on day 14 in rabbits immunized with the S1-Fc fusion protein using a pseudovirus neutralization assay. We demonstrate that the S1-Fc fusion protein is extremely immunogenic, as evidenced by strong antibody titers observed by day 7. In this study, we examined the immunogenicity of CHO-expressed recombinant SARS-CoV-2 S1-Fc fusion protein in mice, rabbits, and monkeys as a potential candidate for a COVID-19 vaccine. Try to buy only from reliable deal sites which provide proper no-questions asked refund period so that you can check the tool properly and then refund it it doesn’t suffice your needs.The COVID-19 outbreak has become a global pandemic responsible for over 2,000,000 confirmed cases and over 126,000 deaths worldwide.Look for the public roadmap and check the changelog to find out how frequently the product is being updated. Observe how founder is responding to the criticism. Look at the reviews and comments about the tool on the deal sales page.If the tool is brand new, check if they have been featured on sites like BetaList, ProductHunt, IndieHackers, HackersNews etc.If so, mostly likely they won’t break the user’s trust. Check if they are publically visible and socially active on channels like LinkedIn, IndieHackers, ProductHunt etc. Search online or look for the ‘Abous Us’ section of the tool to find more info about the founders.Look for the online reviews for this tool on Sites like G2, Capterra, FinanceOnline etc.To avoid the risk of investing in a bad deal, here are a few key things to consider before making the purchase decision –
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |